Professor Matt Stevenson PhD (Lancaster), BSc (Lancaster)
Professor of Health Technology Assessment
The University of Sheffield
Regent Court, 30 Regent Street
Sheffield S1 4DA
Tel: (+44) (0)114 222 0691
Fax: (+44) (0)114 222 0749
I graduated with a PhD in Operational Research from Lancaster University. I am a Member of NICE Technology Appraisal Committee C and the NICE Diagnostic Advisory Committee. I have led numerous projects for NICE and the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC). I am the Director of ScHARR-TAG.
- My research interests are discrete event simulation, individual patient modelling and mathematical modelling within health technology assessment
- I am co-module leader for the advanced simulation module on the Health Economic and Decision Science MSc
- I am an active PhD supervisor (5 current PhD students)
- I am a Member of NICE Appraisal Committee C
- I am a Member of NICE Diagnostic Advisory Committee
- I am a Member of the Centre for Bayesian Statistics in Health Economics
- I have over 50 peer reviewed publications with approximately 20 as primary author (see Full List of Publications in Downloads)
Matt Stevenson is based in Health Economics and Decision Science (HEDS)
- Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. The Lancet, 392(10156), 1403-1412. View this article in WRRO
- Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS ONE, 13(10), e0205013-e0205013. View this article in WRRO
- Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. PharmacoEconomics. View this article in WRRO
- A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis. PharmacoEconomics. View this article in WRRO
- The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate. Journal of Rheumatology, 44(7), 973-980. View this article in WRRO
- Health State Preference Weights for the Glasgow Outcome Scale Following Traumatic Brain Injury: A Systematic Review and Mapping Study. Value in Health, 20(1), 141-151. View this article in WRRO
- A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 1-406. View this article in WRRO
- Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.. Health Technology Assessment, 20(46), 1-246. View this article in WRRO
- Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20(35), 1-610. View this article in WRRO
- Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures: a systematic review and cost-effectiveness analysis.. Health Technol Assess, 18(17), 1-290.
- Diagnosis of DVT: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2 SUPPL.), e351S-e418S.
- Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis. BMC Cancer, 11. View this article in WRRO
- Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial).. Br J Surg, 96(10), 1147-1156.
- Vitamin K to prevent fractures in older women: systematic review and economic evaluation.. Health Technol Assess, 13(45), iii-134.
- Integration of meta-analysis and economic decision modeling for evaluating diagnostic tests. MED DECIS MAKING, 28(5), 650-667.
- Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA.. Health Econ, 16(10), 1009-1023.
- The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.. Health Technol Assess, 11(4), 1-134.
- Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. HEALTH TECHNOL ASSES, 11(7), 1-+.
- Accurate, practical and cost-effective assessment of carotid stenosis in the UK. HEALTH TECHNOL ASSES, 10(30), 1-+.
- Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technology Assessment, 10(15). View this article in WRRO
- A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.. Health Technol Assess, 9(22), 1-160. View this article in WRRO
- Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis.. Med Decis Making, 24(1), 89-100.
- Treatment of established osteoporosis: a systematic review and cost-utility analysis.. Health Technol Assess, 6(29), 1-146.